Previous Article | Next Article ![]()
Infection and Immunity, May 2001, p. 2847-2852, Vol. 69, No. 5
Division of Immunologic and Infectious
Diseases, Children's Hospital of Philadelphia, Philadelphia,
Pennsylvania 19104
Received 11 October 2000/Returned for modification 12 December
2000/Accepted 31 January 2001
Lipopolysaccharide (LPS) is a very potent inducer of tumor necrosis
factor alpha (TNF- Tumor necrosis factor alpha
(TNF- Lipopolysaccharide (LPS) is an integral component of gram-negative
bacterial cell walls which stimulates TNF- Gamma interferon (IFN- In addition to this well-known priming effect, there have been some
studies suggesting that IFN- Tissue culture.
Mono-Mac-6 cells were obtained from the
German Collection of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany) and maintained in RPMI 1640 supplemented with
10% fetal bovine serum, 2 mM glutamine, 100 U of penicillin-6
phosphate per ml, 10 mM minimal essential medium nonessential amino
acids, 10 µg of insulin-transferrin-sodium selenite per ml, and 100 mM sodium pyruvate. Tissue culture media and cell culture supernatants
were periodically screened for endotoxin and mycoplasma. All
plasticware used in these experiments was certified pyrogen-free.
Reagents.
LPS (Escherichia coli O11:B4) and
actinomycin D were obtained from Sigma Chemical Co. (St. Louis, Mo.).
Recombinant human IFN- TNF- RNase protection assay.
Mono-Mac-6 cells were cultured and
stimulated in T-25 tissue culture flasks at 2 × 106
cells/ml. Unless otherwise noted, cells were stimulated with 2 µg of
LPS per ml with or without 50 ng of rhIFN- Statistical analysis.
Student t tests were
performed to determine the statistical significance of TNF- IFN-
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.2847-2852.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Gamma Interferon and Lipopolysaccharide Interact at
the Level of Transcription To Induce Tumor Necrosis Factor Alpha
Expression
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
) expression from monocytes and macrophages. Another inflammatory cytokine, gamma interferon (IFN-
), can
potentiate the effects of LPS, but the mechanism is not thoroughly
understood. Previous reports emphasized the ability of IFN-
to
upregulate CD14 expression (the receptor for LPS), and nearly all
studies have utilized sequential stimulation with IFN-
followed by
LPS to exploit this phenomenon. This study demonstrates that IFN-
can upregulate the effect of LPS at the level of transcription. Human
monoblastic Mono-Mac-6 cells produced up to threefold-greater levels of
TNF-
when simultaneously stimulated with LPS and IFN-
compared to
treatment with LPS alone. RNase protection studies showed a similar
increase in RNA beginning as early as within 30 min. The synthesis of
TNF-
mRNA in IFN-
- and LPS-treated Mono-Mac-6 cells was also
temporally prolonged even though the message turnover rate was
identical to that seen in LPS stimulated cells. The modulatory effect
of IFN-
may be mediated by Jak2.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
) is secreted in response to inflammatory stimuli by
immunologically relevant cells including macrophages, lymphocytes,
natural killer cells, and dendritic cells. Its biological actions
include upregulating the production of proinflammatory cytokines,
chemokines, and adhesion molecules (3). TNF-
produced
inappropriately or excessively may lead to deleterious immunologic
consequences, as is the case in overwhelming sepsis, rheumatoid
arthritis, and systemic lupus erythematosus (1, 20, 36,
43).
production. LPS binds
CD14 and activates the mitogen-activated protein kinase (MAPK)
signaling pathway via p56Lyn (30, 44). LPS also induces NF-
B release from I
B including p50-p65 heterodimers, p50
homodimers, and Rel-p65 heterodimers (7, 37). The
induction of TNF-
by LPS has been widely used to investigate TNF-
transcriptional regulation. NF-
B, as well as C/EBP
and c-Jun, has
been demonstrated to play a role in the regulation of TNF-
transcription in myelomonocytic cells (32, 48, 54). The
ability of LPS to activate multiple inflammatory pathways, including
the upregulation of TNF-
, is believed to be central to the
development of septic shock (10, 35).
) has been shown to prime cells and potentiate
the effects of LPS (23, 24, 33, 49). As IFN-
engages
with its receptor, cytoplasmic Janus kinases (Jak1 and Jak2) become
activated which phosphorylate specific tyrosine residues on the signal
transducers and activators of transcription (STAT)-1
molecules
(9, 40, 53). Activated and phosphorylated STAT1
forms
homodimers, translocates to the nucleus, and binds specific STAT-binding DNA sequences (15, 16). Monocytes and
macrophages become more responsive and sensitive to LPS after
pretreatment with IFN-
(6). Primary human monocytes
increased TNF-
transcription and formed more stable TNF-
mRNA
when they were primed with IFN-
for several hours prior to LPS
stimulation (23, 24, 33, 49). The mechanism underlying the
priming effect appears to be complex. In part, IFN-
upregulates the
receptor for LPS, CD14. It also appears to alter proteins which target
mRNA turnover (42, 47).
may have a direct transcriptional effect. In macrophages isolated from LPS-resistant mice (C3H/HeJ), IFN-
was able to overcome the unresponsiveness of LPS and to induce
TNF-
gene and protein expression (4). Other early
studies have supported the idea that IFN-
may have a direct
transcriptional effect (5, 13, 27). Recent studies have
identified signaling pathways which are coactivated by both LPS and
IFN-
. In one, IFN-
was shown to dramatically augment NF-
B
induction by LPS. This effect required preincubation with IFN-
and
was dependent on protein synthesis (24). A second study
demonstrated that both LPS and IFN-
can lead to phosphorylation of
the proto-oncogene vav (17). This effect was
dependent on the kinase hck, which is known to modulate
TNF-
production. Another signaling pathway in which LPS and IFN-
effect converge is at STAT1. STAT1 is typically considered to be
phosphorylated at Y701 by Jak1 and Jak2. Phosphorylation at S727
potentiates the transcriptional effects of STAT1. The pathway
responsible for phosphorylation of S727 has not been clearly defined;
however, LPS is capable of inducing phosphorylation at that site
(28). Therefore, these studies suggest that LPS and IFN-
may coactivate certain signaling pathways relevant to the transcription of TNF-
. Our studies attempt to define which of the
pathways might underlie the increased TNF-
production from human
cells when both LPS and IFN-
are presented simultaneously as opposed
to a priming strategy. The simultaneous administration of these two
stimuli might mimic the effects of an early in vivo bacterial infection
more closely than a priming strategy. Understanding the interplay
between proinflammatory cytokines could have potential in developing
new cytokine-directed therapeutic strategies for overwhelming
infections or autoimmune diseases.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(rhIFN-
) from Endogen, Inc.
(Woburn, Mass.), had a specific activity of 3 × 107
U/mg. Tyrphostin AG-490 was purchased from Calbiochem (San Diego, Calif.) and suspended in dimethyl sulfoxide (DMSO).
assays.
Mono-Mac-6 cells were plated in
96-well round-bottom tissue culture plates at 2 × 105
cells per 200 µl. Cells were stimulated in duplicates or triplicates with 2 µg of LPS per ml with or without varyious concentrations of
rhIFN-
. After various time points, supernatants were harvested and
were stored at
70°C until enzyme-linked immunosorbent assays (ELISAs) were performed. Human matched antibody pairs for TNF-
were
purchased from Endogen for a conventional sandwich ELISA. Nunc-Immune
Maxisorp plates were coated overnight with capture antibodies [mouse
anti-human TNF-
monoclonal immonoglobulin G1
].
Supernatants from cultures and standard curve TNF-
were allowed to
bind capture antibodies before addition of the biotin-labeled detecting
antibodies [mouse anti-human TNF-
monoclonal immunoglobulin G1(
)]. Streptavidin-conjugated horseradish peroxidase
catalyzing TMB (3,3',5,5'-tetramethylbenzidine) substrate color
conversion was used for detection. Enzyme reactions were terminated by
the addition of 0.18 M H2SO4 before being
measured at 450 nm on the Dynatech MR4000 spectrophotometer (Dynatech
Laboratories, Inc., Chantilly, Va.). ELISA sensitivity was <5.0 pg/ml,
and the backgrounds were negligible.
per ml. In the
experiments to analyze mRNA turnover, actinomycin D at a final concentration of 3 µg/ml was added into the cultures after various periods of time (1, 2, or 4 h). In the experiments to examine the
effects of Jak2 inhibition, AG-490 at a final concentration of 20 µM
was added at the time of initial culture. As a control for the AG-490
diluent, equal volumes of DMSO were added to the second set of
cultures. Culture flasks containing light-sensitive AG-490 were wrapped
in aluminum foil to protect against its deactivation. For time course
studies, approximately 2 × 106 to 4 × 106 cells were removed at designated time points. After
pelleting of the cells, supernatants were removed and saved for ELISAs, while the cell pellets were resuspended in RNAzol B. RNA was isolated utilizing the RNAzol B protocol (Tel-Test, Inc., Friendswood, Tex.).
The quality of RNA was first checked on 1% agarose-formaldehyde gel
prior to further processing. RNase protection assays were performed
using the RiboQuant multiprobe system (Pharmingen, San Diego, Calif.)
by following the manufacturer's instructions. Then, 10 µg of total
RNA was hybridized with radioactive probe. Hybridized RNA was separated
on 5% acrylamide gel and quantified on a PhosphorImager using the
ImageQuant software (Molecular Dynamics, Sunnyvale, Calif.). TNF-
mRNA quantity was normalized to the L32 concentrations in the same
hybridization reaction. Densitometric units were calculated as follows:
(TNF-
/L32) × the average of L32 within the entire set of one experiment.
protein
secretion among sets of stimulated cells. The paired Student
t test was utilized to compare the quantitative differences
of mRNA in the RNase protection assays. A P value of <0.05
was used to indicate significance.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
and LPS induced greater TNF-
production than LPS
alone.
Mono-Mac-6 cells simultaneously treated with LPS and
IFN-
consistently secreted from 1.5- to 3-fold greater amounts of
TNF-
compared to LPS stimulation alone (Fig.
1). This upregulation by IFN-
was dose
dependent. IFN-
alone could not induce TNF-
secretion in repeated
experiments. IFN-
effects were observed with LPS in doses ranging
from 20 ng/ml to 2 µg/ml (data not shown). From these experiments,
LPS at 2 µg/ml and IFN-
at 50 ng/ml were determined to be
concentrations that optimally stimulated TNF-
production in
Mono-Mac-6 cells.

View larger version (16K):
[in a new window]
FIG. 1.
Stimulation of Mono-Mac-6 cells with LPS and IFN-
.
Human Mono-Mac-6 cells (2 x 105 per well) were stimulated
for 5 h with 2 µg of LPS (E. coli O111:B4) per ml,
with increasing concentrations of rhIFN-
. Duplicate ELISAs were
performed as described in Materials and Methods for each sample or
condition from triplicate stimulations. The numbers in parenthesis
above the solid bars indicate the fold increase over LPS stimulation
alone (striped bar). The figure is representative of five separate
experiments.
IFN-
may potentiate the ability of LPS to induce TNF-
by
increasing the rate or efficiency of TNF-
mRNA synthesis.
To
assess whether the effect of IFN-
was mediated at a pre- or a
posttranscriptional level, we compared mRNA production over time in
Mono-Mac-6 cells treated with LPS alone or with a combination of LPS
and IFN-
. Employing the RNase protection assay, TNF-
transcripts
isolated from stimulated cells were hybridized to radiolabeled TNF-
RNA probes. The amount of TNF-
RNA protected from RNase was
quantified and normalized to the L32 RNA (Fig. 2A and
B). Induction of TNF-
mRNA by LPS was
rapid and transient. At the time points analyzed, transcripts
accumulated rapidly between 15 and 45 min post-LPS stimulation and
began to fall progressively after 45 min (Fig. 2B). TNF-
transcripts
harvested from cells stimulated with LPS and IFN-
showed similar
patterns initially. Interestingly, the levels of transcript harvested
from dually stimulated cells did not decline as quickly as in
LPS-stimulated cells (Fig. 2B). Therefore, stimulation with LPS plus
IFN-
seemed to prolong the presence of TNF-
mRNA or alter the
kinetics of transcription. It also suggested that IFN-
modulated
LPS-induced TNF-
production at the transcriptional level.
|
protein secretion over time correlated with
those of the TNF-
mRNA levels. We measured TNF-
secretion in
supernatants of the same Mono-Mac-6 cell cultures where RNA was also
isolated. As measured by sandwich ELISA, TNF-
production by
LPS-stimulated cells began to increase by between 45 and 90 min and
peaked at 180 min or 2 h (Fig. 2C). The peak of protein synthesis was
delayed by approximately 2 hours compared to that of the mRNA (Fig.
2B). Similar kinetics of TNF-
secretion is initially observed for
cells stimulated with both LPS and IFN-
(Fig. 2C). However, LPS- and
IFN-
-treated cells secreted significantly greater amounts of TNF-
after 180 and 300 min of stimulation (P < 0.05). This
correlated strongly with the prolonged presence of TNF-
transcripts
in these cells.
Stability of TNF-
mRNA is comparable in Mono-Mac-6 cells
stimulated with LPS alone or LPS with IFN-
.
To determine
whether the prolonged presence of TNF-
mRNA in LPS- and
IFN-
-treated cells is due to increased stability of the transcripts,
we measured RNA levels accumulated after 1 h of stimulation with
further transcription inhibited. Mono-Mac-6 cells were treated with or
without IFN-
in the presence of LPS. After 1 h, cells were
treated with actinomycin D, a potent inhibitor of RNA
polymerase-dependent transcription. Transcripts that were synthesized
within 1 h were monitored over time and analyzed by the RNase
protection assay (Fig. 3A and B). TNF-
transcripts decreased rapidly 15 to 30 min after synthesis, with the
rate of degradation in LPS- stimulated cells comparable to that in LPS-
and IFN-
-stimulated cells (Fig. 3B). Half-lives of the transcripts were calculated by determining the time at which 50% of the mRNA remained (Fig. 3C). Among three separate experiments, the half-lives of
TNF-
transcripts from cells stimulated by LPS were 28.1 ± 23.7 (mean ± the standard deviation) min without IFN-
and 27.3 ± 21.1 min with IFN-
. Similar rates of mRNA degradation were observed from transcripts accumulated after 2 h (LPS, 27.0 min; LPS plus IFN-
, 24.4 min) and after 4 h (LPS, 22.4 min; LPS plus IFN-
, 21.5 min) of stimulation. This demonstrated that the increase in TNF-
mRNA and protein in LPS- and IFN-
-stimulated cells was not due to increased stability of the transcript. This suggests that
IFN-
acts directly to modulate the LPS-induced TNF-
at the level
of gene transcription. This is unlike the results of previous reports
showing priming with IFN-
for several hours before LPS treatment
both greatly increased TNF-
transcription and enhanced mRNA
stability (23, 42).
|
Inhibition of Jak2 by tyrphostin AG-490 compromised the induction
of TNF-
by LPS with or without of IFN-
.
Our findings of very
rapid induction of TNF-
transcripts by LPS with a prolonged peak
induced by IFN-
could not be explained by changes in message
turnover. This, in turn, suggested that IFN-
was directly activating
transcription in the presence of LPS, although it had no activity on
its own. This could be due to a direct transcriptional effect of
STAT1
or due to an interaction of the IFN-
signaling pathway with
the LPS signaling pathway. To begin to explore the mechanisms of the
modulatory effects of IFN-
, we utilized tyrphostin AG-490, a
competitive inhibitor of Jak2 and Jak3 (8, 26, 34, 52).
AG-490 is a tyrosine kinase inhibitor first identified as an inhibitor
of the expansion of acute lymphoblastic leukemia cells
(34). The kinase activities of Jak1 and of other kinases,
Lck, Lyn, Btk, Syk, and Src, were unaffected by AG-490 (19,
31). Mono-Mac-6 cells were stimulated with LPS with or without
IFN-
; one set of cells was treated with AG-490 and the other with
DMSO carrier as a control. TNF-
gene transcripts from all the
experimental conditions exhibited similar profiles through at least the
first 90 min of stimulation (Fig. 4).
Thereafter, RNA levels began to decline in cells treated with LPS (Fig.
4). TNF-
message from LPS-IFN-
-stimulated cells exhibited the
prolonged peak, as previously shown in Fig. 2B. In the presence of
AG-490, this prolonged transcript synthesis was no longer observed. AG-490 had an unexpected inhibitory effect on LPS-induced TNF-
mRNA
synthesis (Fig. 4). At 130 min, this inhibitory effect was significant
in comparing the amount of transcripts in the LPS versus the LPS- and
AG-490-stimulated cells (P = 0.005). The difference in
the amount of TNF-
mRNA levels between the LPS-IFN-
- versus the
LPS-IFN-
-AG-490-stimulated cells was also significant (P = 0.025). We focused on the 130-min time point since the prolonged presence of TNF-
mRNA was the most obvious in LPS-IFN-
-treated cells, and the inhibitory effects of AG-490 appeared to be the most
marked. At that time point it is clear that AG-490 inhibited TNF-
transcription in cells stimulated with LPS alone even though Jak2 and
Jak3 are not known to play a role in LPS signaling. AG-490 also altered
the kinetics of TNF-
transcript accumulation such that the prolonged
peak typically seen with IFN-
-LPS stimulation was no longer
evident. The most likely explanation for these findings is that the LPS
signaling pathway is altered by Jak2 and/or Jak3 inhibition and that
the loss of the characteristic prolonged peak was due to the expected
inhibition of Jak2 which is required for IFN-
signaling. We cannot
exclude the possibility that AG-490 is having effects on multiple
signaling pathways, however.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we demonstrated that IFN-
could
directly potentiate the ability of LPS to induce the expression of
TNF-
at the level of gene transcription. Human Mono-Mac-6 cells
secreted significantly more TNF-
when stimulated simultaneously with
IFN-
and LPS compared to stimulation with LPS alone. The production of TNF-
mRNA was also prolonged from cells treated with both IFN-
and LPS. This effect was regulated at the level of transcription but
not at the level of message stability since the rate of message degradation was similar whether LPS alone or LPS with IFN-
induced the expression. Our studies suggest that IFN-
has a direct
transcriptional effect in addition to the well-characterized
"priming" activity of IFN-
(23).
The production of TNF-
is regulated at various stages from the
agonist initiation of signaling pathways to the exportation and
cleavage of the mature protein. Interactions of signaling pathways
launched upon receptor engagement remain largely undefined. However,
studies of the promoter region of TNF-
have provided much insight
into the complex choreography of DNA-binding proteins that is
coordinated to initiate transcription and derepress inhibitory transcription repressors (18, 21, 29, 45, 46, 50, 54).
Interactions of NF-
B, C/EBP
, Jun, and other proteins contribute
to the transcriptional regulation of TNF-
. Other studies to
understand the regulation of TNF-
expression have included analyses
of transcription rates, message stability, and targets for mRNA
degradation (11, 14, 39). In our studies, the rapid kinetics and the absence of an effect on message stability strongly suggest that IFN-
modulation of LPS-induced TNF-
expression in
human Mono-Mac-6 cells is at the level of gene transcription.
No definitive conclusions can be drawn as to whether Jak2 took
part in the prolonged presence of TNF-
mRNA in
LPS-IFN-
-stimulated cells because there was a general inhibition of
TNF-
expression. However, it did appear that the characteristic
kinetics seen with LPS-IFN-
stimulation were abolished by AG-490
treatment. This suggests that the effect on the kinetics may be
mediated by Jak2. Potential mechanisms include direct and indirect
effects. The IFN-
potentiation effect could be due to
protein-protein interactions of STAT1
with the LPS-induced
transcription factors on the TNF-
promoter. STAT molecules have been
demonstrated to complex with other transcription factors such as
NF-
B leading to synergistic effects (24).
In addition to altering the characteristic kinetics, AG-490 had
the unexpected effect of inhibiting LPS-induced transcription of
TNF-
. This suggests that it may be acting on shared signaling pathways. The glycosyl-phosphatidylinositol-anchored cell surface receptor, CD14, has been shown to directly associate with a member of
the src family protein tyrosine kinase, p56lyn
(41, 44), to activate the MAPK cascades (30, 38,
55). The MAPK cascade through Raf-1 targets the activation of
c-Jun and c-Fos, components of the AP-1 transcription dimer, to induce
TNF-
expression (22, 25). Both Jak2 and Jak3 can
activate the MAPK cascade, suggesting one potential mechanism for
IFN-
potentiation of LPS induction of TNF-
(12, 51, 52,
55). Our AG-490 data are consistent with that hypothesis. AG-490
would abolish the IFN-
effect on kinetics through its inhibition of
Jak2 and could also affect LPS stimulation due to the intersection of
Jak2 and the MAPK pathway. However, there are other possible
explanations for our data. It is possible that AG-490 targets and
inhibits the phosphorylation of kinases in the LPS signaling pathways.
Another LPS-induced signaling pathway results in the activation of the
NF-
B family of transcription factors which is critical for TNF-
transcription (2, 21, 48, 50).
In summary, we have shown that IFN-
has the ability to upregulate
the LPS-inducible TNF-
mRNA and protein production using a
stimulation protocol which administers IFN-
and LPS simultaneously. The data we present here suggest that the effect is at the level of
gene transcription since mRNA turnover rates were similar in cells
stimulated by LPS with or without IFN-
. This phenomenon could be of
relevance early in the course of bacterial infections when both LPS and
IFN-
would be present at high levels.
| |
ACKNOWLEDGMENTS |
|---|
We thank Laurie Kilpatrick for critical review of the manuscript.
J.Y.L. is a recipient of the National Eye Institute Pre-doctoral Training Grant and the Gina Finzi Memorial Fellowship from the Lupus Foundation of America, Inc. K.E.S. is supported by the Wallace Chair of Pediatrics and the RO1 AI/AR 44127.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Immunologic and Infectious Diseases, Children's Hospital of Philadelphia, 34th St. and Civic Center Blvd., Philadelphia, PA 19104. Phone: (215) 590-4685. Fax: (215) 590-3044. E-mail: sullivak{at}mail.med.upenn.edu.
Editor: S. H. E. Kaufmann
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ashkenazi, A.,
S. A. Marsters,
D. J. Capon,
S. M. Chamow,
I. S. Figari,
D. Pennica,
D. V. Goeddel,
M. A. Palladino, and D. H. Smith.
1991.
Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
Proc. Natl. Acad. Sci. USA
88:10535-10539 |
| 2. |
Barnes, P. J., and M. Karin.
1997.
Nuclear factor- B a pivotal transcription factor in chronic inflammatory diseases.
N. Engl. J. Med.
336:1066-1071 |
| 3. |
Bazzoni, F., and B. Beutler.
1996.
The tumor necrosis factor ligand and receptor families.
N. Engl. J. Med.
334:1717-1725 |
| 4. |
Beutler, B.,
V. Tkacenko,
I. Milsark,
N. Krochin, and A. Cerami.
1986.
Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype.
J. Exp. Med.
164:1791-1796 |
| 5. | Biragyn, A., and S. A. Nedospasov. 1995. Lipopolysaccharide-induced expression of TNF-alpha gene in the macrophage cell line ANA-1 is regulated at the level of transcription processivity. J. Immunol. 155:674-683[Abstract]. |
| 6. | Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:749-795[CrossRef][Medline]. |
| 7. |
Bohuslav, J.,
V. V. Kravchenko,
G. C. Parry,
J. H. Erlich,
S. Gerondakis,
N. Mackman, and R. J. Ulevitch.
1998.
Regulation of an essential innate immune response by the p50 subunit of NF- B.
J. Clin. Investig.
102:1645-1652[Medline].
|
| 8. |
Bright, J. J.,
C. Du, and S. Sriram.
1999.
Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis.
J. Immunol.
162:6255-6262 |
| 9. | Briscoe, J., D. Guschin, N. C. Rogers, D. Watling, M. Muller, F. Horn, P. Heinrich, G. R. Stark, and I. M. Kerr. 1996. JAKs, STATs and signal transduction in response to the interferons and other cytokines. Phil. Trans. R. Soc. London Ser. B Biol. Sci. 351:167-171[Medline]. |
| 10. | Calandra, T., J. D. Baumgartner, G. E. Grau, M. M. Wu, P. H. Lambert, J. Schellekens, J. Verhoef, and M. P. Glauser. 1990. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J. Infect. Dis. 161:982-987[Medline]. |
| 11. |
Carballo, E.,
W. S. Lai, and P. J. Blackshear.
1998.
Feedback inhibition of macrophage tumor necrosis factor- production by tristetraprolin.
Science
281:1001-1005 |
| 12. | Carter-Su, C., and L. S. Smit. 1998. Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Rec. Prog. Hormone Res. 53:61-83. |
| 13. | Chung, I. Y., J. Kwon, and E. N. Benveniste. 1992. Role of protein kinase C activity in tumor necrosis factor-alpha gene expression. Involvement at the transcriptional level. J. Immunol. 149:3894-3902[Abstract]. |
| 14. |
Crawford, E. K.,
J. E. Ensor,
I. Kalvakolanu, and J. D. Hasday.
1997.
The role of 3' poly(A) tail metabolism in tumor necrosis factor-alpha regulation.
J. Biol. Chem.
272:21120-21127 |
| 15. |
Darnell, J. E.,
I. M. Kerr, and G. R. Stark.
1994.
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
Science
264:1415-1421 |
| 16. | Decker, T., P. Kovarik, and A. Meinke. 1997. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J. Interferon Cytokine Res. 17:121-134[Medline]. |
| 17. | English, B. K., S. L. Orlicek, Z. Mei, and E. A. Meals. 1997. Bacterial LPS and IFN-gamma trigger the tyrosine phosphorylation of vav in macrophages: vidence for involvement of the hck tyrosine kinase. J. Leukoc. Biol. 62:859-864[Abstract]. |
| 18. |
Fong, C.-L.,
A. H. Siddiqui, and D. F. mark.
1994.
Identification and characterization of a novel repressor site in the human tumor necrosis factor a gene.
Nucleic Acids Res.
22:1108-1114 |
| 19. | Gazit, A., P. Yaish, C. Gilon, and A. Levitzki. 1989. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 32:2344-2352[CrossRef][Medline]. |
| 20. | Georgopoulos, S., D. Plows, and G. Kollias. 1996. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. 46:86-97[Medline]. |
| 21. |
Goldfeld, A. E.,
C. Doyle, and T. Maniatis.
1990.
Human tumor necrosis factor a gene regulation by virus and lipopolysaccharide.
Proc. Natl. Acad. Sci. USA
87:9769-9773 |
| 22. |
Hambleton, J.,
M. McMahon, and A. L. DeFranco.
1995.
Activation of Raf-1 and mitogen-activated protein kinase in murine macrophages partially mimics lipopolysaccharide-induced signaling events.
J. Exp. Med.
182:147-154 |
| 23. | Hayes, M. P., S. L. Freeman, and R. P. Donnelly. 1995. IFN-gamma priming of monocytes enhances LPS-induced TNF production by augmenting both transcription and MRNA stability. Cytokine 7:427-435[CrossRef][Medline]. |
| 24. |
Held, T. K.,
X. Weihua,
L. Yuan,
D. V. Kalvakolanu, and A. S. Cross.
1999.
Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1.
Infect. Immun.
67:206-212 |
| 25. |
Karin, M., and M. Delhase.
1998.
JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action?
Proc. Natl. Acad. Sci. USA
95:9067-9069 |
| 26. | Kirken, R. A., R. A. Erwin, D. Taub, W. J. Murphy, F. Behbod, L. Wang, F. Pericle, and W. L. Farrar. 1999. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J. Leukoc. Biol. 65:891-899[Abstract]. |
| 27. | Koerner, T. J., D. O. Adams, and T. A. Hamilton. 1987. Regulation of tumor necrosis factor (TNF) expression: interferon-gamma enhances the accumulation of mRNA for TNF induced by lipopolysaccharide in murine peritoneal macrophages. Cell. Immunol. 109:437-443[CrossRef][Medline]. |
| 28. | Kovarik, P., D. Stoiber, M. Novy, and T. Decker. 1998. Stat1 combines signals derived from IFN-gamma and LPS receptors during macrophage activation. EMBO J. 17:3660-3668[CrossRef][Medline]. (Erratum, 17:4210.) |
| 29. |
Kuprash, D. V.,
I. A. Udalova,
R. L. Turetskaya,
D. Kwiatkowski,
N. R. Rice, and S. A. Nedospasov.
1999.
Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide.
J. Immunol.
162:4045-4052 |
| 30. | Kyriakis, J. M., and J. Avruch. 1996. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 18:567-577[CrossRef][Medline]. |
| 31. |
Levitzki, A., and A. Gazit.
1995.
Tyrosine kinase inhibition: an approach to drug development.
Science
267:1782-1788 |
| 32. |
Liu, H.,
P. Sidiropoulos,
G. Song,
L. J. Pagliari,
M. J. Birrer,
B. Stein,
J. Anrather, and R. M. Pope.
2000.
TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta.
J. Immunol.
164:4277-4285 |
| 33. |
Medvedev, A. E.,
T. Flo,
R. R. Ingalls,
D. T. Golenbock,
G. Teti,
S. N. Vogel, and T. Espevik.
1998.
Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappaB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls.
J. Immunol.
160:4535-4542 |
| 34. | Meydan, N., T. Grunberger, H. Dadi, M. Shahar, E. Arpaia, Z. Lapidot, J. S. Leeder, M. Freedman, A. Cohen, A. Gazit, A. Levitzki, and C. M. Roifman. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645-648[CrossRef][Medline]. |
| 35. | Michie, H. R., K. R. Manogue, D. R. Spriggs, A. Revhaug, S. O'Dwyer, C. A. Dinarello, A. Cerami, S. M. Wolff, and D. W. Wilmore. 1988. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318:1481-1486[Abstract]. |
| 36. |
Moreland, L. W.,
S. W. Baumgartner,
M. H. Schiff,
E. A. Tindall,
R. M. Fleischmann,
A. L. Weaver,
R. E. Ettlinger,
S. Cohen,
W. J. Koopman,
K. Mohler,
M. B. Widmer, and C. M. Blosch.
1997.
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
N. Engl. J. Med.
337:141-147 |
| 37. |
Oeth, P. A.,
G. C. Parry,
C. Kunsch,
P. Nantermet,
C. A. Rosen, and N. Mackman.
1994.
Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site.
Mol. Cell. Biol.
14:3772-3781 |
| 38. | Pawson, T. 1995. Protein modules and signalling networks. Nature 373:573-580[CrossRef][Medline]. |
| 39. |
Raabe, T.,
M. Bukrinsky, and R. A. Currie.
1998.
Relative contribution of transcription and translation to the induction of tumor necrosis factor-alpha by lipopolysaccharide.
J. Biol. Chem.
273:974-980 |
| 40. | Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227-264[CrossRef][Medline]. |
| 41. |
Stefanova, I.,
M. L. Corcoran,
E. M. Horak,
L. M. Wahl,
J. B. Bolen, and I. D. Horak.
1993.
Lipopolysaccharide induces activation of CD14-associated protein tyrosine kinase p53/56lyn.
J. Biol. Chem.
268:20725-20728 |
| 42. | Suk, K., and K. L. Erickson. 1996. Differential regulation of tumour necrosis factor-alpha mRNA degradation in macrophages by interleukin-4 and interferon-gamma. Immunology 87:551-558[CrossRef][Medline]. |
| 43. | Sullivan, K. E., C. Wooten, B. Schmeckpeper, D. Goldman, and M. Petri. 1997. A promoter polymorphism of tumor necrosis alpha is associated with systemic lupus erythematosus in African Americans. Arthritis Rheum. 40:2207-2211[Medline]. |
| 44. | Sweet, M. J., and D. A. Hume. 1996. Endotoxin signal transduction in macrophages. J. Leukoc. Biol. 60:8-26[Abstract]. |
| 45. | Takashiba, S., L. Shapira, S. Amar, and T. E. Van Dyke. 1993. Cloning and characterization of human TNF alpha promoter region. Gene 131:307-308[CrossRef][Medline]. |
| 46. | Takashiba, S., T. E. Van Dyke, L. Shapira, and S. Amar. 1995. Lipopolysaccharide-inducible and salicylate sensitive nuclear factor(s) on human tumor necrosis factor alpha promoter. Infect. Immun. 63:1529-1534[Abstract]. |
| 47. | Takeshita, S., K. Nakatani, Y. Takata, H. Kawase, I. Sekine, and S. Yoshioka. 1998. Interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) enhance lipopolysaccharide binding to neutrophils via CD14. Inflamm. Res. 47:101-103[CrossRef][Medline]. |
| 48. | Trede, N. S., A. V. Tsytsykova, T. Chatila, A. E. Goldfeld, and R. S. Geha. 1995. Transcriptional activation of the human TNF-alpha promoter by superantigen in human monocytic cells: role of NF-kappa B. J. Immunol. 155:902-908[Abstract]. |
| 49. | Ucla, C., P. Roux-Lombard, S. Fey, J. M. Dayer, and B. Mach. 1990. Interferon gamma drastically modifies the regulation of interleukin-1 genes by endotoxin in U937 cells. J. Clin. Investig. 85:185-191. |
| 50. |
Udalova, I. A.,
J. C. Knight,
V. Vidal,
S. A. Nedospasov, and D. Kwiatkowski.
1998.
Complex NF-kappaB interactions at the distal tumor necrosis factor promoter region in human monocytes.
J. Biol. Chem.
273:21178-21186 |
| 51. |
Vanderkuur, J. A.,
E. R. Butch,
S. B. Waters,
J. E. Pessin,
K. L. Guan, and C. Carter-Su.
1997.
Signaling molecules involved in coupling growth hormone receptor to mitogen-activated protein kinase activation.
Endocrinology
138:4301-4307 |
| 52. |
Wang, L. H.,
R. A. Kirken,
R. A. Erwin,
C. R. Yu, and W. L. Farrar.
1999.
JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
J. Immunol.
162:3897-3904 |
| 53. | Weber-Nordt, R. M., R. Mertelsmann, and J. Finke. 1998. The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leukemia Lymphoma 28:459-467. |
| 54. |
Yao, J.,
N. Mackman,
T. S. Edgington, and S.-T. Fan.
1997.
Lipopolysaccharide induction of the tumor necrosis factor-a promoter in human monocytic cells.
J. Biol. Chem.
272:17795-17801 |
| 55. |
Zhu, W.,
J. S. Downey,
J. Gu,
F. Di Padova,
H. Gram, and J. Han.
2000.
Regulation of TNF expression by multiple mitogen-activated protein kinase pathways.
J. Immunol.
164:6349-6358 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|